Evidence map›Paper›PMID 35198608›Full record

ReviewFrontiers in cardiovascular medicine2021

Cognitive Impairment in Heart Failure: Landscape, Challenges, and Future Directions.

Mengxi Yang, Di Sun, Yu Wang, Mengwen Yan, Jingang Zheng, Jingyi Ren

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cardiovascular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 71 citations in OpenAlex.

  1. Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Trial
  2. Trial
  3. Trial
  4. Cognition in Cardiovascular Disease.Current neurology and neuroscience reports · 2026
    Review
  5. Review
  6. Heart Meets Brain: Insights into Neurocardiac Pathophysiology.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Observational
  14. A novel composite biomarker score for the identification of cognitive impairment in patients with heart failure: a pilot study.Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2025
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mengxi YangHeart Failure Center, China-Japan Friendship Hospital, Beijing, China.
Di SunHeart Failure Center, China-Japan Friendship Hospital, Beijing, China.
Yu WangDepartment of Neurology, China-Japan Friendship Hospital, Beijing, China.
Mengwen YanHeart Failure Center, China-Japan Friendship Hospital, Beijing, China.
Jingang ZhengHeart Failure Center, China-Japan Friendship Hospital, Beijing, China.
Jingyi RenHeart Failure Center, China-Japan Friendship Hospital, Beijing, China.
China-Japan Friendship Hospital · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) is a major global healthcare problem accounting for substantial deterioration of prognosis. As a complex clinical syndrome, HF often coexists with multi-comorbidities of which cognitive impairment (CI) is particularly important. CI is increasing in prevalence among patients with HF and is present in around 40%, even up to 60%, of elderly patients with HF. As a potent and independent prognostic factor, CI significantly increases the hospitalization and mortality and decreases quality of life in patients with HF. There has been a growing awareness of the complex bidirectional interaction between HF and CI as it shares a number of common pathophysiological pathways including reduced cerebral blood flow, inflammation, and neurohumoral activations. Research that focus on the precise mechanism for CI in HF is still ever insufficient. As the tremendous adverse consequences of CI in HF, effective early diagnosis of CI in HF and interventions for these patients may halt disease progression and improve prognosis. The current clinical guidelines in HF have begun to emphasize the importance of CI. However, nearly half of CI in HF is underdiagnosed, and few recommendations are available to guide clinicians about how to approach CI in patients with HF. This review aims to synthesize knowledge about the link between HF and cognitive dysfunction, issues pertaining to screening, diagnosis and management of CI in patients with HF, and emerging therapies for prevention. Based on data from current studies, critical gaps in knowledge of CI in HF are identified, and future research directions to guide the field forward are proposed.

Indexed as

cognitive impairmentdiagnosisepidemiologyheart failuremanagementpathophysiology

Identifiers

PMID35198608
PMCPMC8858826
OpenAlexW4213305570

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.